Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents (Q58480211)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

Francesca Romana Spinelli

10 February 2020

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Claudio M. Mastroianni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Rossana Scrivo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Fabio Mengoni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Giancarlo Iaiani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Anna Rita Vestri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Roberta Priori

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Elisa Di Filippo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Manuela Di Franco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Vincenzo Vullo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Guido Valesini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

5 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

1567-1575

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Influence of previous tuberculin skin test on serial IFN-γ release assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

The New IGRA and the Old TST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-012-2049-6

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial

1 reference

12 December 2020

Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population

1 reference

12 December 2020

Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis.

1 reference

12 December 2020

Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration

1 reference

12 December 2020

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay

1 reference

12 December 2020

Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment

1 reference

12 December 2020

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

12 December 2020

Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts

1 reference

12 December 2020

Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study.

1 reference

12 December 2020

Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment.

1 reference

12 December 2020

Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay

1 reference

12 December 2020

Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment

1 reference

12 December 2020

Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.

1 reference

12 December 2020

Classification criteria for psoriatic arthritis: development of new criteria from a large international study

1 reference

12 December 2020

Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy

1 reference

12 December 2020

10.1007/S10067-012-2049-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22864811%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference